Call Options

17 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 15, 2024

SELL
$27.7 - $35.48 $299,160 - $383,183
-10,800 Reduced 67.08%
5,300 $154,000
Q4 2023

Feb 14, 2024

BUY
$26.32 - $34.31 $244,776 - $319,083
9,300 Added 136.76%
16,100 $543,000
Q3 2023

Nov 14, 2023

BUY
$30.68 - $40.09 $208,624 - $272,612
6,800 New
6,800 $208,000
Q2 2022

Aug 08, 2022

SELL
$51.49 - $81.64 $56,639 - $89,804
-1,100 Reduced 78.57%
300 $17,000
Q1 2022

May 16, 2022

SELL
$60.03 - $76.49 $6,003 - $7,648
-100 Reduced 6.67%
1,400 $107,000
Q4 2021

Feb 14, 2022

BUY
$47.97 - $62.21 $71,955 - $93,315
1,500 New
1,500 $90,000
Q3 2021

Nov 15, 2021

SELL
$54.64 - $61.3 $573,720 - $643,650
-10,500 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$59.18 - $69.99 $621,390 - $734,895
10,500 New
10,500 $637,000
Q1 2020

May 15, 2020

SELL
$28.4 - $50.7 $269,800 - $481,650
-9,500 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$36.31 - $46.83 $344,945 - $444,885
9,500 New
9,500 $430,000
Q3 2019

Nov 14, 2019

SELL
$35.66 - $44.99 $28,527 - $35,992
-800 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$36.57 - $47.97 $29,256 - $38,376
800 New
800 $35,000
Q1 2019

May 15, 2019

SELL
$36.47 - $42.17 $481,404 - $556,644
-13,200 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$41.31 - $52.16 $1.34 Million - $1.69 Million
-32,400 Reduced 71.05%
13,200 $568,000
Q3 2018

Nov 14, 2018

BUY
$32.85 - $52.0 $1.5 Million - $2.37 Million
45,600 New
45,600 $2.24 Million
Q3 2017

Nov 14, 2017

SELL
$35.7 - $39.5 $85,680 - $94,800
-2,400 Closed
0 $0
Q2 2017

Aug 14, 2017

BUY
N/A
2,400
2,400 $115,000

Others Institutions Holding PCRX

About Pacira BioSciences, Inc.


  • Ticker PCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 45,824,200
  • Market Cap $870M
  • Description
  • Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...
More about PCRX
Track This Portfolio

Track Walleye Trading LLC Portfolio

Follow Walleye Trading LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Trading LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Trading LLC with notifications on news.